Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | I332Pfs*14 |
Impact List | frameshift |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 I332Pfs*14 indicates a shift in the reading frame starting at amino acid 332 and terminating 14 residues downstream causing a premature truncation of the 393 amino acid Tp53 protein (UniProt.org). I332Pfs*14 induces DNA-damage related senescence in one of two cell lines, however, results in increased Tp53 stability and nuclear localization, and decreased oligomerization, DNA binding, and transactivation of Tp53 targets, and leads to altered cell cycle in cultured cells (PMID: 34045312). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon10 TP53 I332Pfs*14 TP53 mutant TP53 inact mut TP53 I332Pfs*14 |
Transcript | NM_000546.6 |
gDNA | chr17:g.7670715_7670716insGG |
cDNA | c.994-1_994insCC |
Protein | p.I332Pfs*14 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126112.3 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7670715_7670716insGG | c.994-1_994insCC | p.I332Pfs*14 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|